Ignite Creation Date:
2025-12-24 @ 11:51 PM
Ignite Modification Date:
2026-06-10 @ 8:00 AM
Study NCT ID:
NCT02966951
Status:
UNKNOWN
Last Update Posted:
2021-04-28
First Post:
2016-11-15
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Use of Adipose Tissue Derived Mesenchymal Stem Cells for Knee Osteoarthrosis
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D020370', 'term': 'Osteoarthritis, Knee'}, {'id': 'D010003', 'term': 'Osteoarthritis'}], 'ancestors': [{'id': 'D001168', 'term': 'Arthritis'}, {'id': 'D007592', 'term': 'Joint Diseases'}, {'id': 'D009140', 'term': 'Musculoskeletal Diseases'}, {'id': 'D012216', 'term': 'Rheumatic Diseases'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 10}}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'RECRUITING', 'startDateStruct': {'date': '2017-01-17', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2021-04', 'completionDateStruct': {'date': '2021-12', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2021-04-27', 'studyFirstSubmitDate': '2016-11-15', 'studyFirstSubmitQcDate': '2016-11-15', 'lastUpdatePostDateStruct': {'date': '2021-04-28', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2016-11-17', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2021-09', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Evaluation of the safety and tolerability of the intra articular injection', 'timeFrame': 'Time Frame: 6 months', 'description': 'patients will be monitored for any adverse events resulting from the intraarticular injection of ATMSC'}], 'secondaryOutcomes': [{'measure': 'Assessment of the efficacy of intra-articular injection of ATMSC', 'timeFrame': '12 months', 'description': 'The efficacy of the intra-articular injection of ATMSC will be assessed by Magnetic Resonance Imaging (MRI).'}]}, 'oversightModule': {'isUsExport': False, 'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['osteoarthrosis', 'knee', 'adipose tissue', 'stem cells', 'cell therapy'], 'conditions': ['Knee Osteoarthrosis']}, 'descriptionModule': {'briefSummary': 'Adipose tissue derived Mesenchymal Stem cells (ATMSC) will be injected in patients diagnosed with Knee osteoarthrosis', 'detailedDescription': 'Ten patients from both genders diagnosed with Knee osteoarthrosis, will be enrolled according to specific inclusion and exclusion criteria. These patients will be injected with Adipose Tissue derived Mesenchymal Stem Cells. Then, they are followed by clinical assessment, laboratory investigations as well as magnetic resonance imaging (MRI) of the injected knee.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '75 Years', 'minimumAge': '42 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\nSevere KOA stage III or IV by Laurance \\& Kellgren staging as judged by Posterioranterior (PA) Xray of the knee joint.\n\nWilling to participate by signing the informed consent\n\nExclusion Criteria:\n\n* Sublaxation beyond 20 degrees of the bones of the knee joint\n* Oral anticoagulants or heparin therapy\n* Heart failure or arrhythmia\n* Body Mass Index \\> 35\n* Uncontrolled Diabetes Mellitus.\n* Evidence of Infectious Diseases.\n* Active infection\n* Malignancy\n* Pregnancy\n* Anemia less than 11g/dl or thrombocytopenia less than 100,000 or leucopenia less than 3000.\n* Unreliable patients\n* Non-resident in Jordan'}, 'identificationModule': {'nctId': 'NCT02966951', 'briefTitle': 'Use of Adipose Tissue Derived Mesenchymal Stem Cells for Knee Osteoarthrosis', 'organization': {'class': 'OTHER', 'fullName': 'University of Jordan'}, 'officialTitle': 'Knee Osteoarthrosis (KOA) in Jordanian Patients: a Phase I Dose-finding Study Using Adipose Tissue Derived Mesenchymal Stem Cells (ATMSC) for Advanced Stage III and IV KOA', 'orgStudyIdInfo': {'id': 'ATKneeUJCTC'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'adipose tissue mesenchymal stem cell', 'description': 'Intra-articular adipose tissue derived mesenchymal stem cell injection will be given for each patient in 2 doses, 50 million of ATMSC in each dose', 'interventionNames': ['Biological: Adipose tissue derived mesenchymal stem cell']}], 'interventions': [{'name': 'Adipose tissue derived mesenchymal stem cell', 'type': 'BIOLOGICAL', 'description': 'Intra-articular adipose tissue derived mesenchymal stem cell injection.', 'armGroupLabels': ['adipose tissue mesenchymal stem cell']}]}, 'contactsLocationsModule': {'locations': [{'zip': '11942', 'city': 'Amman', 'status': 'RECRUITING', 'country': 'Jordan', 'contacts': [{'name': 'Abdalla Awidi, MD', 'role': 'CONTACT', 'email': 'abdalla.awidi@gmail.com', 'phone': '0096265355000'}], 'facility': 'Cell Therapy Center', 'geoPoint': {'lat': 31.95522, 'lon': 35.94503}}], 'centralContacts': [{'name': 'Hanan Jafar, PhD', 'role': 'CONTACT', 'email': 'hanan.jafar@gmail.com', 'phone': '00962798871087'}], 'overallOfficials': [{'name': 'Abdallah Awidi, MD', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Cell Therapy Center'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Hanan Jafar', 'class': 'OTHER'}, 'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR', 'investigatorTitle': 'Researcher', 'investigatorFullName': 'Hanan Jafar', 'investigatorAffiliation': 'University of Jordan'}}}}